These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16470587)

  • 1. Genetic alterations in urothelial bladder carcinoma: an updated review.
    Mhawech-Fauceglia P; Cheney RT; Schwaller J
    Cancer; 2006 Mar; 106(6):1205-16. PubMed ID: 16470587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular changes in development and progression of urothelial carcinoma].
    Hartmann A
    Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathways of urothelial development and bladder tumorigenesis.
    Castillo-Martin M; Domingo-Domenech J; Karni-Schmidt O; Matos T; Cordon-Cardo C
    Urol Oncol; 2010; 28(4):401-8. PubMed ID: 20610278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
    Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR
    Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation.
    Zhang ZT; Pak J; Huang HY; Shapiro E; Sun TT; Pellicer A; Wu XR
    Oncogene; 2001 Apr; 20(16):1973-80. PubMed ID: 11360181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling.
    van der Kwast TH; Bapat B
    Curr Opin Urol; 2009 Sep; 19(5):516-21. PubMed ID: 19553819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.
    Billerey C; Chopin D; Aubriot-Lorton MH; Ricol D; Gil Diez de Medina S; Van Rhijn B; Bralet MP; Lefrere-Belda MA; Lahaye JB; Abbou CC; Bonaventure J; Zafrani ES; van der Kwast T; Thiery JP; Radvanyi F
    Am J Pathol; 2001 Jun; 158(6):1955-9. PubMed ID: 11395371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis.
    Gao J; Huang HY; Pak J; Cheng J; Zhang ZT; Shapiro E; Pellicer A; Sun TT; Wu XR
    Oncogene; 2004 Jan; 23(3):687-96. PubMed ID: 14737103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.
    Wolff EM; Liang G; Jones PA
    Nat Clin Pract Urol; 2005 Oct; 2(10):502-10. PubMed ID: 16474624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium.
    Goebell PJ; Knowles MA
    Urol Oncol; 2010; 28(4):409-28. PubMed ID: 20610279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
    Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
    Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular genetics of bladder cancer: targets for diagnosis and therapy.
    Baffa R; Letko J; McClung C; LeNoir J; Vecchione A; Gomella LG
    J Exp Clin Cancer Res; 2006 Jun; 25(2):145-60. PubMed ID: 16918124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.
    Lascombe I; Clairotte A; Fauconnet S; Bernardini S; Wallerand H; Kantelip B; Bittard H
    Clin Cancer Res; 2006 May; 12(9):2780-7. PubMed ID: 16675571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urothelial tumorigenesis: a tale of divergent pathways.
    Wu XR
    Nat Rev Cancer; 2005 Sep; 5(9):713-25. PubMed ID: 16110317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.
    Lindgren D; Liedberg F; Andersson A; Chebil G; Gudjonsson S; Borg A; Månsson W; Fioretos T; Höglund M
    Oncogene; 2006 Apr; 25(18):2685-96. PubMed ID: 16532037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
    Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
    J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated genomic and transcriptional analysis of the in vitro evolution of telomerase-immortalized urothelial cells (TERT-NHUC).
    Chapman EJ; Williams SV; Platt FM; Hurst CD; Chambers P; Roberts P; Knowles MA
    Genes Chromosomes Cancer; 2009 Aug; 48(8):694-710. PubMed ID: 19405089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research advances on bladder cancer associated genes].
    Zhang R; Zhang JJ; He ZG; Cheng SJ; Gao YN
    Ai Zheng; 2003 Jan; 22(1):104-7. PubMed ID: 12561447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.